Pesquisar um ensaio clínico
Outras opções de pesquisa
43 Resultado(s)
Ensaio em fase de recrutamento = 
; Ensaio a decorrer = 
; Ensaio concluído = 
; Financiado por um membro do IRDiRC = 
; Membro de uma ERN = 
Ensaio (s) clínico (s) nacional (is)
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1) -DE
Institution: Information not provided - DE
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
PHYOX 7: A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment, With or Without Dialysis -DE
Institution: Information not provided - DE
ALEMANHA
Nordrhein-Westfalen
BONN
ePHex OLE: An open-label single-arm treatment extension study to evaluate the long-term efficacy and safety of Oxabact® for patients with primary hyperoxaluria who completed study OC5-DB-02 -DE
Universitäts-Kinderklinik Bonn
Abteilung für allgemeine Pädiatrie und Poliklinik
ALEMANHA
Nordrhein-Westfalen
BONN
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients with Primary Hyperoxaluria Type 1 - DE
Universitätsklinikum Bonn (AöR)
Universitätsklinikum Bonn
ALEMANHA
Nordrhein-Westfalen
BONN
ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 -DE-
Universitätsklinikum Bonn (AöR)
Universitätsklinikum Bonn
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1) - BE
Cliniques universitaires Saint-Luc - UCLouvain
Centre de Référence des Maladies Rénales Rares
BELGICA
LIEGE
LIEGE
ePHex OLE: An open-label single-arm treatment extension study to evaluate the long-term efficacy and safety of Oxabact® for patients with primary hyperoxaluria who completed study OC5-DB-02 - BE
CHU de Liège - Site du Sart Tilman
Néphrologie
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
PHYOX 7: A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment, With or Without Dialysis -ES
Institution: Information not provided - ES
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-TermAdministration of ALN-GO1 in Patients with Primary Hyperoxaluria Type 1- GB
Institution: Information not provided - US
FRANCA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients with Primary Hyperoxaluria Type 1 - FR
Institution: Information not provided - FR
FRANCA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
PHYOX 7: A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment, With or Without Dialysis - FR
Institution: Information not provided - FR
FRANCA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1) -FR
Institution: Information not provided - FR
FRANCA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria - PHYOX3 -FR
Institution: Information not provided - FR
FRANCA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
PHYOX8: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nedosiran in Pediatric Patients From Birth to 5 Years of Age With Primary Hyperoxaluria and Relatively Intact Renal Function -FR
Institution: Information not provided - FR
JAPAO
JAPAN
ADDRESS : NOT PROVIDED - JP
Long Term Extension Study in Patients With Primary Hyperoxaluria (PHYOX3) (PHYOX3)
Institution: Information not provided - JP
PAISES BAIXOS
Utrecht
ADDRESS: NOT PROVIDED - NL
ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1) - NL
Institution: Information not provided - NL
REINO UNIDO
Greater London
ADDRESS: NOT PROVIDED - GB
PHYOX8: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nedosiran in Pediatric Patients From Birth to 5 Years of Age With Primary Hyperoxaluria and Relatively Intact Renal Function -GB
Institution: Information not provided - GB
REINO UNIDO
Greater London
LONDON
ePHex OLE: An Open-label Single-arm Treatment Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact for Patients With Primary Hyperoxaluria Who Completed Study OC5-DB-02-GB
Royal Free London Hospital
University College London, Centre for Nephrology
REINO UNIDO
West Midlands
BIRMINGHAM
ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 -GB
Birmingham Children's Hospital NHS Foundation Trust
SUICA
Suisse Alémanique
BERN
ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1) - CH
Universitätsspital Inselspital
Universitätsklinik für Nephrologie und Hypertonie
SUICA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 - CH
Institution: Information not provided - CH
ALEMANHA
Sachsen
LEIPZIG
ADVANCE: A randomized, double-blind, placebo-controlled, multinational, multicenter study with open-label treatment extension to assess the effect of MIN-102 on the progression of adrenomyeloneuropathy in male patients with X-linked adrenoleukodystrophy (Phase II-III) -DE-
Universitätsklinikum Leipzig AöR
Klinik und Poliklinik für Neurologie
ESPANHA
Cataluña
BARCELONA
ADVANCE: A randomized, double-blind, placebo-controlled, multinational, multicenter study with open-label treatment extension to assess the effect of MIN-102 on the progression of adrenomyeloneuropathy in male patients with X-linked adrenoleukodystrophy - ES
Hospital Universitari Vall d'Hebron
Servicio de Neurología
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy
Institution: Information not provided - US
ITALIA
LAZIO
ROMA
ALD-104 - A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects 0 to 17 Years of Age With Cerebral Adrenoleukodystrophy (CALD) - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
REINO UNIDO
Greater London
ADDRESS: NOT PROVIDED - GB
ADVANCE: A randomized, double-blind, placebo-controlled, multinational, multicenter study with open-label treatment extension to assess the effect of MIN-102 on the progression of adrenomyeloneuropathy in male patients with X-linked adrenoleukodystrophy - GB
Institution: Information not provided - GB
ALEMANHA
Hamburg
HAMBURG
An Open-label, Multicenter Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) -DE
UKE - Universitätsklinikum Hamburg-Eppendorf
Arbeitsgruppe Degenerative Gehirnkrankheiten
ALEMANHA
Niedersachsen
GÖTTINGEN
An Open-label, Multicenter Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) -DE
Universitätsmedizin Göttingen
Klinik für Kinder- und Jugendmedizin
ESPANHA
Cataluña
ESPLUGUES DE LLOBREGAT
NEXUS: An exploratory, open-label, multicenter study in male pediatric patients with cerebral X-linked Adrenoleukodystrophie (cALD) to assess the effect of MIN-102 treatment on the progression of cerebral lesions - ES
Hospital Sant Joan de Déu Barcelona
FRANCA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
An Open-label, Multicenter Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) -FR
Institution: Information not provided - FR
Ensaio (s) clínico (s) multinacional (ais)
ESTADOS UNIDOS
Massachusetts
CAMBRIDGE
ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
Alnylam Pharmaceuticals, Inc.
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-TermAdministration of ALN-GO1 in Patients with Primary Hyperoxaluria Type 1
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1/2, Single-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of Subcutaneously Administered ALN-GO1 in Healthy Adult Subjects, and Patients with Primary Hyperoxaluria Type 1
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1 Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1).
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
PHYOX3: An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
PHYOX 7: A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment, With or Without Dialysis
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
PHYOX8: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nedosiran in Pediatric Patients From Birth to 5 Years of Age With Primary Hyperoxaluria and Relatively Intact Renal Function.
Institution: Information not provided - US
SUECIA
Region Stockholm
ADDRESS: NOT PROVIDED - SE
ePHex OLE: An Open-label Single-arm Treatment Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact for Patients With Primary Hyperoxaluria Who Completed Study OC5-DB-02
Institution: Information not provided - SE
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
ADVANCE: A randomized, double-blind, placebo-controlled, multinational, multicenter study with open-label treatment extension to assess the effect of MIN-102 on the progression of adrenomyeloneuropathy in male patients with X-linked adrenoleukodystrophy
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
NEXUS: An Open-label, Multicenter Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)
Institution: Information not provided - ES
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US